The Rho-associated coiled-coil-containing protein serine/threonine kinases ROCK-I and ROCK-II are thought to play a major role in cytoskeletal dynamics by serving as downstream effectors of the Rho/Rac family of cytokine-and growth factoractivated small GTPases. As such, the ROCK family members are attractive intervention targets for a variety of pathologies, including cancer and cardiovascular disease. The authors developed a high-throughput screen to identify ROCK-II inhibitors and report results from a direct comparison of 2 screening campaigns for ROCK-II inhibitors using fluorescence polarization (FP) and filter binding (FB). Screening protocols to identify inhibitors of ROCK-II were developed in FB and FP formats under similar assay and kinetic conditions. A 30,000-member compound library was screened using FB ( 33 P) and FP detection systems, and compounds that were active in either assay were retested in 5-point curve confirmation assays. Analysis of these data showed an approximate 95% agreement of compounds identified as active in both assay formats. Also, compound potency determinations from FB and FP had a high degree of correlation and were considered equivalent. These data suggest that the assay methodology has little impact on the quality and productivity of the screen, provided that the assays are developed to standardize kinetic conditions. (Journal of Biomolecular Screening 2003:399-409) Hubert et al. 408 www.sbsonline.org Journal of Biomolecular Screening 8(4); 2003 FIG. 9. Bland and Altman 26 equivalence analysis of the ROCK-II fluorescence polarization (FP) and filter-binding (FB) confirmed actives.
INTRODUCTION
R ho, Rac, and Cdc42-all members of the Ras superfamily of monomeric guanosine triphosphate (GTP)-binding proteins-are molecular switches that regulate many essential cellular processes, including actin dynamics, gene transcription, cell cycle progression, and cell adhesion (for a review, see Bishop and Hall 1 ) . In particular, a major function of Rho GTPases is to regulate the assembly and organization of the actin cytoskeleton. 1 Geranylgeranyl-modified Rho GTPases are able to interact with the plasma membrane and, through a pool of at least 30 known effectors, elicit their biological effects in response to growth factor and cytokine stimulation. Interaction of Rho with downstream effectors such as serine/threonine kinases is thought to lead to activating conformational changes in the effectors via Rho binding to the Rho effector homology region of the target protein. 1 For Rho-activated kinases, the most common mechanism of effector activation involves the disruption of intramolecular autoinhibitory interactions, leading to an unveiling and activation of the kinase domain. Known downstream kinase effectors of Rho/Rac proteins include the ROCK family (Rho-associated coiled-coil-containing protein S/T kinase; ROCK-I and ROCK-II), PI-4-kinase, PAK (1, 2, and 3), Citron, LIMK, and myosin light chain kinase (MLCK). [1] [2] [3] [4] [5] [6] Recent evidence has implicated Rho kinases in the pathogenesis of both cancer and hypertension, with the majority of reports centered on the oncogenic potential of this kinase family. Rho-dependent processes, including ROCK activation, may play a pivotal role in tumor metastasis. ROCK phosphorylation of substrates MLC, MLC phosphatase, and LIMK results in cytoskeletal reorganization, a necessary component of tumorigenesis. 7 Adhesion of tumor cells to host layers and subsequent transcellular migration are crucial steps in cancer cell invasion and metastasis. Serum-dependent ROCK activity is directly implicated in tumor cell migration and invasion in metastatic breast cancer and hepatoma cell lines in vitro. 8 Expression of a dominant negative ROCK construct, as well as treatment of cells with the ROCK-specific inhibitor Y27632, attenuates serum-induced tumor cell invasion of rat hepatoma cells, implying a direct role for this kinase in invasive and metastatic processes. 8 Furthermore, constitutively active Rho proteins are found in a variety of primary human tumors suggestive of overactivation of downstream effectors such as ROCK. As for a role in the pathogenesis of hypertension, Y27632 inhibition of ROCK suppressed Rho-induced formation of stress fibers in HeLa cells and, more important, reduced blood pressure following p.o. treatment of spontaneously hypertensive rats. 9 These data suggest that inhibitors of ROCK proteins in vivo may serve as useful anticancer or antihypertensive agents. To date, the majority of published evidence indicates that ROCK-I plays a role in disease progression, whereas the relative contribution of ROCK-II to disease progression remains unclear.
High-throughput screening (HTS) to identify kinase inhibitors was initiated in the late 1980s and early 1990s primarily to identify inhibitors of receptor protein tyrosine kinases (for a review, see Myers et al. 10 ). The majority of these early biochemical assays relied on the detection of radiolabeled phosphate incorporation into peptide and protein substrates using filter binding and the more recent scintillation proximity assay (SPA) technology. 11, 12 Although filtration technology has evolved into a much higher throughput format and remains the gold standard by which other formats are judged, a number of newer technologies that offer the promise of higher throughput, nonradioactive detection are available. Fluorescence polarization (FP), enhanced chemiluminescence (ECL), and microfluidics (MF) are a few of the technologies that the drug discovery industry is evaluating in an effort to increase kinase lead generation. [13] [14] [15] A recent industry survey indicated an expected doubling of compound throughput between 2001 and 2003, with a 62% increase in the number of compounds tested per screen. 16 This increase in laboratory productivity is fueled by technological advances that are coupled to the need to analyze a greater number of targets identified through genomic and proteomic efforts each year.
Despite the dramatic increase in the number of kinase targets screened over the past few years, there is still little agreement across the industry as to the comparability of different screening formats. Although various reports comparing traditional radioactive kinase technologies to the newer antibody-based fluorescent formats indicate a favorable degree of data concordance (as judged by overlapping IC 50 values using commercially available kinase inhibitors), these reports did not expand their technology comparison to include evaluation of data generated in HTS campaigns. [17] [18] [19] Sills et al. 20 recently reported a large-scale kinase assay format comparison using SPA, FP, and homogeneous time-resolved fluorescence (HTRF) formats to evaluate data from a 30,000compound screen against an unnamed tyrosine kinase. Their a priori assumption was that HTS active compound identification was independent of assay technology; the same hits would always be identified. Therefore, Sills et al. designed, optimized, and evaluated each kinase assay format independently. Active compounds were identified in each screen and then tested in a concentrationresponse format in each of the 3 assays. The active rate was set to 0.1% to 0.2% for each assay, although the sensitivity of the formats varied, resulting in the production of "active" compound sets of different size and membership.
The Sills et al. 20 paper concluded that different assay technologies lead to the identification of different sets of hit compounds, with a degree of overlap much less than anticipated. In addition, compound potency comparisons between SPA and the fluorescent assays indicated a different and unexplained profile of activity, although the SPA was indicated as their assay of choice based on the identification of what were later determined to be the "true hits" using this technology. The authors extended the potency profile difference to also include single-point primary screening data in which "inherent lack of precision in the primary screening process" resulted in the misidentification of active compounds, depending on the assay format.
Our intent was to compare kinase assay technologies using assays that were codeveloped to minimize variations in kinetics while establishing nearly uniform assay conditions. To achieve this goal, we evaluated enzyme kinetics (K m for adenosine triphosphate (ATP), substrate and reaction linearity with respect to time) using both filter binding (FB) and FP formats that allowed us to establish nearly identical assay buffer conditions. Testing of commercially available kinase inhibitors confirmed the comparable sensitivity and performance of each format. HTS to identify ROCK-II inhibitors was independently conducted using both assay technologies, and the resulting pooled set of active compounds was confirmed in 5-point potency evaluations using the same compound source plates. The FP data were converted to reflect the amount of product formed. This data conversion was necessary to capture additional active compounds from the FP assay and allowed a more direct comparison of the IC 50 values generated in the 2 formats. Our results surprisingly indicated that there was a 95% agreement in the number of compounds identified in both formats. The majority of the compounds identified in FP but not FB were determined to be fluorescent (and therefore not a true ROCK-II inhibitor) or had weak activity in FB. We therefore conclude that both the FP and FB formats are suitable, sensitive methods for identification of ROCK-II inhibitors and that high levels of concordance can be obtained by developing assays under uniform assay conditions and comparable kinetics.
MATERIALS AND METHODS

Compound preparation
Compounds were delivered in NUNC V-bottom plates (Fisher Scientific #245128, Pittsburgh, PA) and prepared as 5 µL of a 2-mM solution in 100% DMSO. Compounds were diluted to 200 µL with 2.5% DMSO in diH 2 0, resulting in a final compound of 50 µM. A Multimek 96 (Beckman, Fullerton, CA) was used to transfer either 20 µL (FB) or 5 µL (FP) of the 50-µM compound to the reaction plate. Compounds were diluted 1:5 in the reaction mixture for a 10-µM final concentration. For 5-point IC 50 determinations, compounds were serially diluted in 5% DMSO. The same source compound plates were used for potency determinations in the 2 assay formats.
FB assay
The 100-µL filter binding reactions were carried out in NUNC clear V-bottom polystyrene plates as described above. The reaction buffer consisted of 25 mM MOPS/6.3 mM EGTA/31 mM βglycerophosphate/1.25 mM sodium orthovanadate/0.02% Triton X-100/1.25 mM dithiothreitol (DTT) (added fresh daily), pH 7.3. Following the 20-µL compound transfer, the RFARKGSLRQKNV ("RFARK") peptide substrate (SynPep #01-3-30-3-LIL, Dublin, CA), ATP, MgCl 2 , and [γ 33 P]ATP (Perkin Elmer Life Sciences, Inc., #NEG602H, Boston, MA) were prepared in the reaction buffer. A Multidrop (Titertek, Huntsville, AL) was used to dispense 40 µL of the above cofactor/substrate mixture to the reaction plates for a final reaction concentration of 50 µM peptide substrate, 10 µM ATP, 13.5 mM MgCl 2 , and 0.5 µCi [γ 33 P]ATP/well. Rat ROCK-II enzyme, consisting of amino acids 1-543 (Upstate Biotechnology #14-338, Lake Placid, NY), was prepared at 0.125 milliunits/µL in reaction buffer, and 40 µL was added to the reaction plates by Multidrop to initiate the reaction. The reaction was incubated at room temperature for 90 min and quenched by dispensing 75 µL of 10% H 3 PO 4 with a Multidrop, followed by transfer of 150 µL of the quenched reaction mix to phosphocellulose FB plates (Millipore #MAPHNOB50, Bedford, MA) prewet for 10 min with 0.75% H 3 PO 4 . Following a 1-h room-temperature incubation, the plates were extracted and washed 3 times with 200 µL of 0.75% H 3 PO 4 using a Microplate Assay Processor (MAP, Titertek, Huntsville, AL). The filter support was removed from the filter plate and manually replaced with a Multiscreen Adapter (Packard #A242-212, Boston, MA). A Multidrop was then used to dispense 100 µL of Microscint-20 scintillation fluid (Packard, Boston, MA), the plates were sealed using a Presto Sealer (Zymark, Hopkinlin, MA), and the amount of [γ 33 P]-labeled substrate was assessed by scintillation counting for 30 sec per well on a TopCount-NXT (Packard, Boston, MA) configured for 33 P. The results were analyzed using either GraphPad Prism software (San Diego, CA) or customized S-Plus software.
FP assay
The FP assay was developed using the filtration format reaction buffer and the Panvera Protein Kinase C assay kit (Panvera #P2748, Madison, WI). The 25-µL reaction was carried out in 384well black opaque plates (Costar #3710, Corning, NY). The reaction buffer was identical to the filter-binding reaction buffer and consisted of 25 mM MOPS/6.3 mM EGTA/31 mM βglycerophosphate/1.25 mM sodium orthovanadate/0.02% Triton X-100/1.25 mM DTT (added fresh daily), pH 7.3. Following the 5-µL compound transfer, the RFARK substrate, ATP, MgCl 2 , and Tracer (fluorescence-labeled phosphopeptide) were prepared in the reaction buffer, and, using a Multidrop, 10 µL was dispensed to the reaction plates for a final concentration of 50 µM peptide substrate, 10 µM ATP, 13.5 mM MgCl 2 , and 5× Tracer. ROCK-II enzyme was prepared at 0.05 milliunits/µL in reaction buffer, and 10 µL was added to the reaction plates by Multidrop for a final con-centration of 0.5 milliunits in a 25-µL reaction volume. This concentration was 10-fold less than that of the filtration assay and was necessary to yield a suitable HTS window. The reaction was incubated at room temperature for 90 min and quenched per the manufacturer's instructions by dispensing 25 µL of a 1:2 solution consisting of the antiphosphoserine antibody and protein kinase C (PKC) quench buffer. The plates were then incubated at room temperature for 4 to 8 h to allow for antibody binding. The fluorescence polarization of each well was read using an Analyst HT (Molecular Devices, Sunnyvale, CA), and data were analyzed using either GraphPad Prism or S-Plus customized software. Fluorescent, nonkinase inhibitory molecules were identified by fluorescent intensity values greater than 15% above background intensity.
RESULTS AND DISCUSSION
To effectively compare ROCK-II FB and FP HTS assays, we evaluated simple assay kinetics using both formats. The initial design of the ROCK-II FB assay used S6 peptide substrate (RRRLSSLRA 21 ) to identify active compounds from the primary ROCK-II FB screen. For the purpose of building similar assays and comparing data for both FB and FP, however, all subsequent assays used as substrate a peptide derived from the PKCalpha pseudosubstrate peptide RFARKGSLRQKNV ("RFARK" 22 ). This substrate is sold as part of a commercially available kinase kit designed for PKC assay development but is also known to be a substrate for other AGC and related kinases such as PKA, GSK3β, and, in this instance, ROCK-II. 23 Buffer composition was established for the ROCK-II assays, as indicated in Materials and Methods, and will not be discussed further other than to indicate that both assays ultimately used nearly identical assay buffers (the FB assay also contained a trace amount of [γ-33 P]-ATP), with the only difference being the enzyme concentration (Table 1 ). To generate an assay window suitable for HTS, the FB assay required a 10-fold higher concentration of enzyme than did the FP assay. For the K m determinations, either ATP or RFARK was held at high concentration (100 µM for each), whereas the concentration of the other factor was varied. The data indicate that regardless of the assay technology employed, ROCK-II had essentially the same af- Final assay conditions for the filter binding and fluorescence polarization (FP) assays were identical, including buffer components, with the exception of enzyme concentration (10fold less in FP). One milliunit (mU) of ROCK-II is equivalent to 2 ng. ATP, adenosine triphosphate.
finity for ATP and the RFARK peptide ( Fig. 1A, B ). The ATP K m value determined for either assay also agrees with a published ROCK-II value derived using traditional filter mat technology. 21 The ROCK-II ATP K m value was the same, regardless of the use of the S6 peptide or the RFARK peptide as substrate (data not shown).
To effectively compare FB and FP data, we converted the assay output to product formed, a data conversion that is critical for accurate evaluation of FP data. A data transformation of the FB CPM readout is not necessary as the amount of radioactivity per well essentially corresponds to the amount of product formed (as there is only one known phosphorylation site for ROCK-II in the S6 peptide substrate, and our detector efficiency for 33 P is 95%; data not shown), provided the phosphocellulose filter is not saturated. The milliP (mP) value output for a standard antibody-based competitive FP assay (such as the one sold by Panvera) is only linear with respect to product formed over a narrow range of concentrations, and therefore a standard curve must be generated for each new FP assay that is developed ( Fig. 2A ). Both the log-linear and linearlinear plots of the data demonstrate that compounds yielding mP signals falling outside of the linear portion of the respective curves will lead to inaccurate estimation of compound activity, which leads to the generation of false negatives during HTS (Fig. 2B) . A more detailed analysis of the linear-linear plot indicates that the assay is linear with respect to product over an extremely narrow range of concentrations, roughly from 0 to 25 nM (Fig. 2, inset) . Outside of this concentration range, any given change in mP is not proportional to a change in product formed.
In our ROCK-II FP assay, in which the percentage conversion of substrate to product is less than 1%, the range of product formed is~30 to 80 nM (data not shown), values that fall outside the linear (with respect to product) portion of the curve. As we typically identify primary screen active compounds based on a 50% change in assay signal (in the case of the FP assay, this corresponds to a 50% increase in mP), this effect can have a profound influence on inhibitor identification. This observation/effect was described nearly 30 years ago in the data analysis of the radioimmunoassay of competitive protein binding from a variety of biochemical systems. 24 Antibody-based FP assays are similar in concept to these competi- tive assays in that a fluorescently tagged peptide product competes with a nontagged peptide product for binding to a phosphospecific antibody. Depending on the activity of a potential inhibitory compound as reflected by a change in mP, a 35% increase in our ROCK-II FP assay mP value typically equals a 50% decrease in product formed. To ensure that compounds capable of eliciting > 50% inhibition of product formation are selected for follow-up from each HTS run, we determined the mP value threshold to be used for each run. Our data indicate that the assay window (mP) varies from day to day and from target to target, necessitating the need to establish a daily conversion factor for mP to product formed, based on the mP versus product standard curve, to accurately establish the active compound threshold (data not shown). Conversion of mP data to product formed also affects the determination of the assay time course, as the reaction remains linear with respect to time nearly 25% longer (~30 min) upon conversion of mP data to product formed (Fig. 3) . Conversion of the mP data to product formed brings the FP assay time course in line with that of the FB assay, further supporting the similar kinetic nature of ROCK-II in both systems. The conversion of the data from CPM to product formed does not affect the enzyme kinetics but rather increases our accuracy in their determination. For our HTS format comparison, both assays were incubated for 90 min. The commercially available small molecule ROCK inhibitor, Y27632, 9 was evaluated in both the FP and FB assays (Fig. 4) . The FB IC 50 value of 230 nM is in agreement with previously published values for both ROCK-I inhibition (140 nM 9 ) and ROCK-II inhibition (98 nM 21 ), whereas the IC 50 of 1.2 µM in the FP assay (using unconverted data) is nearly 6-fold higher than the FB value ( Fig. 4 [cf. open circles vs. closed triangles]). Both assays included 3 independent determinations done in triplicate on the same day using common reagents. This experiment has been repeated multiple times, and we typically see a 2-to 6-fold increase in the Y27632 IC 50 when mP is used for the potency calculation (data not shown). Once again, the importance of converting the FP data from mP to product formed becomes critical for an accurate determination of ROCK-II kinase activity and, ultimately, compound potency. The Y27632 concentration curve based on product formed is nearly identical to that of the FB curve ( Fig. 4 [cf. open vs. closed circles]), with an IC 50 value of 277 nM. This potency "shift" following conversion of mP values to product formed has obvious effects on assay format comparison data but, more important, can affect data interpretation and potential structure-activity relationship trends. For instance, the kinase selectivity profile of potential lead compounds can be a determining factor in deciding which chemical series to ultimately pursue. Inappropriate analysis of FP kinase data may mislead scientists engaged in kinase lead generation into thinking a given compound's potency against an unrelated kinase is actually less than its true value. Of course, this argument presupposes that filter-binding assays are an industry-approved "gold standard" for determining kinase inhibition. Although this point is certainly arguable, we have tested Y27632 as well as multiple inhouse kinase inhibitors in a ROCK-II microfluidic mobility shift assay (which directly measures the concentration of both substrate and product in a reaction) and determined IC 50 s that are in line with our FB values, suggesting that FB data are accurate indicators of compound potency (data not shown).
Under final, nearly identical assay conditions (Table 1) , both the ROCK-II FB and FP assays yield robust screening windows when viewed in either a CPM or mP format (Fig. 5 ). Each scatter plot consists of representative assay window data from 1 set of 2 plates each, tested on the same day and showing either fully active enzyme ("maximum" control) or enzyme fully inhibited with 1 µM staurosporine ("minimum" control, or background). Note that in competitive FP kinase assays, increased kinase activity corresponds to decreasing mP. From these data, Z′ factor calculations were made to determine the robustness of the assays, 25 and values of 0.60 and 0.63 were calculated for the FB and FP assays, respectively ( Fig. 5 ). Assays with Z′ factors above 0.50 are considered to be robust and suitable for HTS. 25 Although the assays were suitable for HTS based on their Z′ factor, the appropriate active threshold for the FP assay was not immediately clear. The data of Figure 2 indicate that identification of HTS active compounds based on mP values is inaccurate and could lead to the generation of a number of false negatives that, when based on product formed, actually inhibit the assay at or above our standard 50% inhibitory threshold. In fact, when the data of Figure 5 are converted from mP to product formed, it becomes evident that a 50% increase in mP signal is equivalent to a 65% inhibition of product formed (Fig. 6 ). It bears repeating, therefore, that a 50% increase in mP does not accurately reflect what is occurring in the assay, and if the HTS active compound threshold is not adjusted accordingly, then many compounds with inhibition in the true 50% to 65% inhibition range will be missed. As single-point determination of compound activity is dependent on a variety of factors coming together in the well of a microplate, it is likely that some relatively potent kinase inhibitors will be missed by the assay if the active compound threshold is not based on product formed. As mentioned previously, due to the variability associated with making up biological assay components daily, the most reliable and accurate way to identify inhibitors using competitive FP is to establish the mP to product formed conversion factor based on each day's HTS data.
Having established equivalence between the ROCK-II FB and FP assays with respect to assay kinetics and sensitivity to commercially available kinase inhibitors, we elevated our comparison to address the question of equivalence on a much larger scale, a full 30,000-compound medium-throughput screening campaign. Using compound source plates from a common stock, a 30,000member small molecule library was assayed at 10 µM in HTS mode in both the FB and FP ROCK-II assays. Unlike a previously published kinase assay format comparison, 20 we made no effort to triage the number of active compounds identified in the rapid screen prior to potency determination but instead chose all of the compounds that inhibited at or above 50% product formed. Of the FIG. 4 . Y27632 IC 50 determinations in both the ROCK-II fluorescence polarization (FP) and filter-binding (FB) assays. IC 50 determinations for Y27632, a commercially available ROCK-II inhibitor, are comparable in FB and FP assay formats when milliP (mP) are converted to product formed using a standard curve, as shown in Figure 2 . If mP are not converted to product formed, there is a significant discrepancy in potency values, demonstrating the importance in correctly analyzing data. Error bars represent error from an average of 3 independent determinations, each done in triplicate.
approximately 700 HTS active compounds that inhibited the FB assay signal by at least 50%, 290 potential ROCK-II kinase inhibitors with an IC 50 at or below 10 µM were subsequently confirmed ( Fig. 7) . Because the confirmation rate of compounds identified in our primary FB kinase assays is generally less than what is typically observed for our FP kinase assays, we chose to immediately generate potencies for the FB assay active compounds to reduce the number of compounds that would ultimately be tested in both formats. The FP MTS was then conducted and yielded 472 active compounds that inhibited product formation by at least 50% (~30% increase in mP). No attempt to eliminate fluorescent compounds was made prior to FP assay potency determination.
The 472 FP assay active compounds were combined with the 290 FB confirmed active compounds to yield 524 compounds that were subsequently tested in 5-point potency evaluations using both formats. Of the compounds, 238/524 (45%) were common to both formats and indicated that both primary assay formats were capable of identifying unique and common sets of compounds. Surprisingly, the FP MTS identified 82% (238/290) of the confirmed actives identified in the FB assay. This percentage overlap plummets to below 50% if the active compound threshold was not adjusted to reflect product formation. Unlike with the FB assay, however, compounds were not triaged from the FP assay prior to subsequent FIG. 6 . Effect of the conversion of milliP (mP) to product formed on the ROCK-II assay window. Converting fluorescence polarization (FP) raw data from mP to product formed using a standard curve, as described in the analysis of the FP data, revealed that a 50% increase in signal (mP) does not correspond to 50% inhibition of product formed. This is apparent when raw data (top rank) are converted to product formed using a standard curve (bottom rank), as shown in Figure 2 . In this example, an approximate 35% increase in signal (mP) is equivalent to 50% inhibition of product formed.
format comparison experiments. Ultimately, 307/524 (56%) compounds yielded a calculable IC 50 in the FB assay, an increase of 27 compounds over the number of confirmed actives identified from the exclusive FB MTS effort, whereas 348/524 (66%) confirmed in the FP assay. Overall, 293/524 (56%) of the compounds yielded a calculable IC 50 in both assays. Using FB as the gold-standard assay format, 293/307 (95%) compounds were identified using FP. Of the 14 FB confirmed active compounds that did not yield a calculable IC 50 in FP, 3 were highly colored and thus quenched the assay, whereas the remaining 11 were weak inhibitors with an IC 50 > 5 µM. Using FP as the gold standard, 293/348 (84%) were identified by FB. Of the 55 compounds that did not yield a calculable IC in FB, 19 were fluorescent (and thus unlikely to be ROCK-II inhibitors), 26 displayed weak sub-50% inhibitory activity in FB, and 7 were weak inhibitors with an IC 50 > 5 µM in FP. Eliminating the contribution of the fluorescent compounds to the analysis, there was an 89% agreement in the number of confirmed actives identified in both assays. Despite the significant differences in how both assays detected kinase activity, the degree of overlap in identified ROCK-II kinase inhibitors is surprisingly high and indicates that the steps taken to standardize the reactions were successful. The biology of the kinase reaction was independent of the format chosen for the detection of kinase activity and, as such, allowed for a meaningful comparison of the 2 different detection systems' ability to identify ROCK-II kinase inhibitors. However, our analyses thus far have not examined the correlation and equivalence of potency data from the 2 formats, only that 2 different kinase assay technologies essentially identify the same set of active compounds from a compound library. Correlation analysis was therefore performed on the FB and FP data and showed a high correlation. The correlation coefficient of the FB IC 50 values to the unconverted FP IC 50 values was r = 0.95 ( Fig. 8) and suggests a strong relationship between FP and FB data. For instance, a compound with a high IC 50 value in FP is likely to have a high FB IC 50 value; similarly, a low FP IC 50 value corresponds to a low FB IC 50 value. On the basis of the correlation analysis, we might conclude that both converted and unconverted FP data are comparable to FB values and that there is no advantage in converting the FP values to product formed. Although we have shown that FP and FB data are highly correlated, our goal is also to test whether FP and FB kinase assays will give similar IC 50 values. As suggested by Bland and Altman, 26 a correlation analysis is not sufficient to demonstrate the equivalence of 2 methods. For example, 2 methods, termed A and B, may be tested for data equivalence. Method A could give results of 2, 4, 5, and 8, and method B could give results of 20, 40, 50, and 80. These 2 methods would be perfectly correlated (r = 1) but are obviously not equivalent.
To determine the relative activity of hits identified in the screens, we further compared the IC 50 values obtained in each assay for each compound. The difference was calculated as the log FP -log FB, where FP is the IC 50 value of a single compound from the FP assay, and FB is the IC 50 value of the same compound in the FB assay ( Fig. 9 ). The differences were plotted against our best estimate of the true value for each compound, that is, the mean of the compound IC 50 value from FP and FB. The mean is calculated as [(log FP + log FB)/2] and was done for every compound screened.
To test for data equivalence, the average and standard deviation of the compound IC 50 differences were calculated. Both an average difference of zero and a small standard deviation of the difference indicate equivalence. For the unconverted FP to FB IC 50 values, the average difference equals 0.185 ± 0.018, indicating a significant disagreement between FP and FB IC 50 determinations. The average fold difference between FP and FB IC 50 s was 1.5, suggesting in general that the FP assay yields less potent hits. The standard deviation of the compound differences using the unconverted FP data was 0.137. The range in which most differences between the 2 methods would occur is the average ± 2 times the standard deviation. Bland and Altman 26 call this range the limits of agreement. For unconverted FP and FB data, the limits of agreement were FIG. 7. ROCK-II fluorescence polarization (FP) and filter-binding (FB) format comparison flow scheme. A total of 30,000 kinase-biased compounds were screened in FB and FP assay formats. Compounds that confirmed in a follow-up FB assay (290) and were active in an initial FP screen (472) were ordered for potency determination in both assays using the same source of compound plates (total of 524 compounds ordered). The assay formats had a 95% overlap with respect to the traditional filtration format in identifying ROCK-II inhibitors. Of the 14 compounds that confirmed in the FB assay but not in the FP format, all the nonfluorescent compounds (11) were weak inhibitors (IC 50 > 5 µM) that did have activity in the FP format below the active threshold. Of the 55 compounds that confirmed in the FP format but not the FB assay, 26 had no activity in FB (19 of these were fluorescent and 7 were weak FP inhibitors) and 29 had activity in the filtration format below the active threshold.
-0.088 to 0.458. When the limits of agreement range were transformed out of the log scale, there was a fold difference of 0.8 to 2.9. Therefore, although the correlation of unconverted FP to FB IC 50 values was very high, the IC 50 values were skewed toward FP.
When the FP potency values were converted to product formed, the average difference was greatly reduced to -0.030 ± 0.016 ( Fig.  9) . This difference is both significant and much closer to zero than the unconverted FP data. When the average difference was transformed into a linear scale, the converted FP to FB data yielded a more desirable average fold difference of 0.93 (a fold difference of 1 corresponds to perfect equivalence). The standard deviation of the differences between converted FP and FB was 0.137, practically identical to the standard deviation of unconverted FP to FB differences. For converted FP to FB IC 50 values, the limits of agreement were -0.304 to 0.244. When this range was transformed into a linear scale, the limits of agreement corresponded to a fold difference range of 0.5 to 1.75.
Our analysis indicated that FP and FB IC 50 values were highly correlated for ROCK-II inhibitors. We have also shown the importance of studying the equivalence of the 2 methods. It is through this analysis that the benefit of converting the FP data to product formed becomes clear, whereas before the conversion, the FP assay consistently gave higher IC 50 values than FB. We showed that converting the FP data did not significantly affect the range of differences between FP and FB IC 50 values; rather, once this conversion was done, FB and FP data were not only highly correlated but also were nearly equivalent.
In summary, we have presented data demonstrating that 2 distinctly different ROCK-II HTS kinase assay formats, filter binding and fluorescence polarization, identified nearly the same small molecule inhibitors from a 30,000-compound screen. Unlike previously reported kinase assay format comparisons, we designed our ROCK-II FB and FP assays under similar kinetic conditions with the goal of revealing the potential equivalence of the detection formats while minimizing variability associated with the individual kinase assays. These changes allowed for an accurate comparison of the 2 detection formats by virtually eliminating assaydependent variables. Thus, the "biology" of each ROCK-II assay was essentially the same. Our data indicate that there is both a high degree of correlation and, more important, near equivalence in the IC 50 values of ROCK-II kinase inhibitors identified using either FP or FB assays. Although it is impossible to draw the larger conclusion that all FP and FB kinase assays are equivalent based on just 1 assay format comparison, additional comparison data from our company indicate that a variety of protein kinase C FP and FB assays run under similar kinetic conditions also yielded nearly identical results, provided that the FP mP to product formed data conversion is made (data not shown). Currently, our laboratory is extending kinase assay format comparisons to include microfluidic mobility shift assays, and preliminary data indicate that this novel format may be equal or even superior to FP and FB technologies. Ultimately, the goal of lead generation is to create a robust and reliable filter for the identification of potential lead candidates. A clear understanding of the concordance of different as- The correlation values are also similar; therefore, it is not clear if there is value in converting the data based on correlation analysis alone. Equivalence of the methods must also be tested. If the 2 methods were equivalent, the best-fit line would lie on the equality line. When FP data are converted to product formed, the lines are significantly closer and cross each other, but they do not with the unconverted data.
say formats simplifies the design of the lead generation strategy pursued for a particular target class. Only once confidence in a particular format is achieved can other variables, such as cost, throughput, and so forth, be considered.
